Freenome
Private Company
Total funding raised: $500.5M
Overview
Freenome is a pioneering diagnostics company developing a multiomics and AI-powered platform for early cancer detection via blood tests. Founded in 2014 and headquartered in South San Francisco, the company's lead program is a blood-based screening test for colorectal cancer (CRC), which is undergoing validation in the large-scale PREEMPT CRC study. Freenome is also expanding its pipeline into lung cancer detection and aims to create a broad, accessible screening platform to improve cancer outcomes through earlier intervention.
Technology Platform
A multiomics platform combining computational biology, machine learning, and analysis of multiple data types from blood (e.g., cell-free DNA, methylation, fragmentomics, proteins) to detect early-stage cancer.
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Freenome competes in the crowded liquid biopsy for early detection market against companies like Exact Sciences (Cologuard, MCED), Guardant Health (Shield), and Grail (Galleri). Differentiation is based on its multiomics platform and the scale of its clinical validation studies.